Cytokine release syndrome
MONDO:0600008A syndrome that occurs after therapeutic infusion of antibodies into the blood and is characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of breath. It is caused by the release of cytokines from the cells that are targeted by the antibodies. Most patients experience a mild to moderate reaction; however, the reaction may be severe and life-threatening.
Also known as: CRS, cytokine storm, cytokine-associated toxicity
33 clinical trials for this condition and its sub-types.
Follow this condition to get notified about new trialsBroader categories
-
New hope: drug may prevent dangerous reactions to cancer immunotherapy
Disease control Not yet recruitingThis study tests whether the drug emapalumab can prevent severe side effects (cytokine release syndrome and nerve-related toxicity) in people with lymphoma or multiple myeloma receiving bispecific antibody therapy. About 60 adults will take emapalumab before their cancer treatmen…
Phase 2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Timing is everything: new trial aims to save lives from immune storm
Disease control Not yet recruitingThis study compares two strategies for starting the drug etoposide in adults with severe hemophagocytic lymphohistiocytosis (HLH) who are in the intensive care unit. HLH is a life-threatening overreaction of the immune system that can cause organ failure. The goal is to see if gi…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New CAR t therapy targets two proteins to fight blood cancers
Disease control Not yet recruitingThis early-phase trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD20) on B cell cancer cells. It is for adults with B cell leukemia or lymphoma who have run out of standard options, including commercial CAR T cells. The main goal is to check safe…
Phase 1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
A steroid premedication may tame the immune reaction to a melanoma therapy
Prevention Not yet recruitingThis phase 2 trial tests whether a low dose of the steroid dexamethasone, given before the first four infusions of tebentafusp, can prevent cytokine release syndrome in people with advanced uveal melanoma. Tebentafusp is a standard first-line treatment for this eye cancer, but it…
Phase 2 • Sponsor: University of California, San Diego • Aim: Prevention
Last updated Sep 05, 2026 00:00 UTC
-
CAR-T breakthroughs come with infection risks – new study aims to decode them
Knowledge-focused Not yet recruitingThis study follows adults with multiple myeloma or B-cell lymphoma who receive CAR-T cell therapy, a powerful immune treatment. Researchers track infections that occur in the first year after treatment, looking at how common they are, what causes them, and which factors raise the…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
New device aims to tame inflammation in Kids' heart surgery
Knowledge-focused Not yet recruitingThis study tests a special filter (Jafron HA-60) used during heart-lung bypass in 20 children having open-heart surgery. The filter is designed to remove inflammatory substances from the blood, which may help reduce complications. The main goal is to see if using the filter is sa…
Sponsor: Centre Hospitalier Universitaire Vaudois • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC